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VIROTHERAPY 
A MODERN CANCER TREATMENT 
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CANCER FACTS 
 Cancers figure among the leading causes of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 million cancer 
related deaths in 2012. 
 
 The number of new cases is expected to rise by about 70% over the next two 
decades. 
 
 Cancer causing viral infections such as HBV/HCV and HPV are responsible 
for up to 20% of cancer deaths in low- and middle-income countries (2). 
 
 It is expected that annual cancer cases will rise from 14 million in 2012 to 
22 within the next 2 decades. 
 
 The financial costs of cancer have been estimated at $1.2 trillion dollars per 
year 
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CCANCER TREATMENTS 
 
 Surgery 
 Chemotherapy 
 Radiation Therapy 
 Targeted Therapy 
 Immunotherapy 
 Stem Cell Transplant 
 Photodynamic Therapy 
 Lasers in Cancer Treatment 
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CLASSIC TREATMENTS SIDE EFFECTS 
 damage to normal cells causes side effects, Normal cells usually 
recover when therapy is over 
 
 The fast-growing, normal cells most likely to be affected are: 
 
 - blood cells forming in the bone marrow  
 
 - cells in the digestive tract (mouth, stomach, intestines, esophagus) 
 
 - reproductive system (sexual organs) 
 
 - hair follicles. 
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CLASSIC TREATMENTS SIDE EFFECTS 
 Fatigue 
 Nausea & Vomiting 
 Pain 
 Hair Loss 
 Anemia 
 Infection 
 Blood Clotting Problems 
 Mouth, Gum and Throat Problems 
 Diarrhea and Constipation 
 Nerve and Muscle Effects 
 Effects on Skin and Nails 
 Kidney and Bladder Effects 
 Flu-Like Symptoms 
 Fluid Retention 
 Effects on Sexual Organs and Sexuality 
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TARGETED THERAPY IN CANCER 
 Targeted therapy is a newer type of cancer 
treatment that uses drugs or other substances 
to more precisely identify and attack cancer 
cells 
 
 …usually little damage to normal cells. 
 
 Targeted therapy is a growing part of many 
cancer treatment regimens. 
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Hormone therapies 
Signal transduction 
inhibitors 
Apoptosis inducers 
Gene expression 
modulators 
Angiogenesis inhibitors 
oncolytic virus therapy 
gene therapy 
Monoclonal antibodies that 
deliver toxic molecules 
Cancer vaccines 
Immunotherapies  
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WHAT IS VIROTHERAPY? 
 
 Virotherapy is an experimental form of cancer treatment using biotechnology 
to convert viruses into cancer-fighting agents by reprogramming viruses to 
attack cancerous cells, while healthy cells remained relatively undamaged... 
 
  Viral oncotropism is a term used to define the ability or property of viruses 
to find and destroy ( oncolysis ) malignant  tumour cells, without harming 
healthy cells.  
 
 Modern Approach to Cancer Treatment Without Borders 
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VIROTHERAPY ADVANTAGES: 
Virotherapy has many advantages compared to chemotherapy and 
radiotherapy:  
 
 Virotherapy induces selective oncolysis of sensitive tumours 
 
 Virotherapy has little or no side effects.  
 
 Virotherapy has a high therapeutic index, in some cases even 
10000:1 (10000 tumour cells break down in relation to 1 healthy 
cell). 
 
 Virotherapy activates the immune system. 
 
 The products of tumour cell breakdown are excreted quicker. 
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VIROTHERAPY SUBCATEGORIES 
 There are 4 main branches of virotherapy:  
 
 anti-cancer oncolytic viruses 
 Viral vectors for gene therapy 
 Viral immunotherapy 
 Drug Delivery (virosom) 
 
 
 virotherapy can also refer more broadly to the use of viruses to 
treat certain medical conditions (like Infections) by killing 
pathogens… 
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VIRAL GENE THERAPY 
 uses non-replicating viruses to deliver therapeutic genes to cells with genetic 
malfunctions. 
 
 first conceptualized in 1972. 
 first FDA-approved in 1990 
 By January 2014, about 2,000 clinical trials had been conducted or had 
been approved 
 
 uncontrolled delivery of a gene and Immune responses to viral therapies is 
most problems in this method. 
 
 ProSavin is one of a number of therapies in the Lentivector. It delivers to the 
brain the genes for three enzymes important in the production of dopamine, 
a deficiency of which causes Parkinson's disease 
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VIRAL IMMUNOTHERAPY 
 viral immunotherapy uses genetically engineered viruses to 
present a specific antigen to the immune system. 
 
 That antigen could be from any species of virus, bactera or 
even human disease antigens, for example cancer antigens... 
 
 Trovax is an immunotherapy that uses a pox-virus bearing the 
tumour antigen 5T4, to induce an immune response against 
a variety of cancer types.  
 
 Ebula vaccine production by this method is Under 
investigation… 
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VIROSOME DRUG DELIVERY  
 Virosomes is A novel strategy for Drug Delivery and 
Targeting.. 
 
 virosomes are biocompatible, biodegradable, nontoxic, and 
non-autoimmunogenic, attempts have been made to use 
them as vaccines or adjuvants as well as delivery systems 
for drugs, nucleic acids, or genes for therapeutic purposes. 
 
 To enhance the efficiency of Drug delivery by the introduction 
of molecules directly into cells, virosomes have been 
developed by combining liposomes with fusiogenic viral 
envelope proteins. 
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ONCOLYTIC VIROTHERAPY 
 
 The use of (oncotropic / oncolytic) viruses in oncology is called 
Oncolytic virotherapy.  
 
 modify existing viruses to create new oncolytic viruses that are 
less susceptible to immune suppression while more specifically 
targeting particular classes of cancer cells. 
 
 similarly as radiotherapy and chemotherapy, causes cell 
breakdown (cytolysis). 
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HISTORY 
In 1904 in Italy a woman confronted two life-threatening events: first, 
diagnosis with cancer of the uterine cervix, then a dog bite. 
 
Doctors delivered the rabies vaccine for the bite, and subsequently her 
“enormously large” tumor disappeared.The woman lived cancer-free 
until 1912. 
 
Soon thereafter several other Italian patients with cervical cancer also 
received the vaccine (a live rabies virus that had been weakened). 
 
As reported by Nicola De Pace in 1910, tumors in some patients shrank, 
presumably because the virus somehow killed the cancer. All eventually 
relapsed and died, however. 
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HISTORY 
 In the 1940s and 1950s, studies were conducted in animal models 
to evaluate the use of viruses in the treatment of tumours and some 
of the earliest human clinical trials with oncolytic viruses were 
started… 
 
But Stoped Until 1990s, because: 
 
 uncertainty about its mechanisms and how to use viruses to achieve 
cures. 
 
 a dearth of tools with which to engineer more e ective viral strains 
 
 the habitual reluctance of physicians to infect patients with 
pathogens. 
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WHAT IS AN ONCOLYTIC VIRUS 
 
 An oncolytic virus is a virus that preferentially infects and 
kills cancer cells. 
 
 the infected cancer cells are destroyed by lysis, they release 
new infectious virus particles to help destroy the remaining 
tumour… 
 
 Oncolytic viruses are thought not only to cause direct 
destruction of the tumour cells, also to stimulate host      anti-
tumour immune responses. 
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PROGRAMMABLE  BIOLOGICAL  MACHINES 
 Herpes simplex virus 
 Adenovirus 
 Measles virus 
 Reovirus 
 Vaccinia virus 
 …. 
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HOW… ?! 
 advances in molecular engineering has allowed for 
manipulation of the viral genome to both make them safer by 
deleting viral genes involved in pathogenesis and by insertion 
of novel transgenes to enhance antitumor activity… 
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Tumour  Targeting concept 
Using Antigenic And Internal differences between healthy and 
cancerous cell to to design a specific lytic virus that Attach or 
replicate in cancerous cells only….. 
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transductional 
Non 
transductional 
Transcriptional 
Translational 
Micro-RNA   
Physiological  
Tumour  targeting 
Double targeting with both transductional and non-transductional targeting 
methods is more effective than any one form of targeting alone. 
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TUMOR-SPECIFIC  TARGETING  STRATEGIES 
 (A) Transductional targeting, based on 
the specific binding of the virus to 
specific or overexpressed cell 
membrane receptors on tumor cells 
  
 (B) Transcriptional targeting, based 
on cell specific transcription of an 
essential viral gene under control of a 
tissue- or tumor specific cellular 
promoter 
 
 (C) Physiological targeting,   using the 
differences in innate immunity 
pathways between normal and tumor 
cells 
 
 (D) micro-RNA based targeting, 
focusing on tissue-specific 
degradation of the viral genome in 
healthy cells. 
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TRANSDUCTIONAL TARGETING 
 involves modifying the viral coat proteins to target tumour 
cells while reducing entry to non-tumour cells.  
 
 This approach to tumour selectivity has mainly focused on 
adenoviruses and HSV-1, although it is entirely viable with 
other viruses. 
 
 2 main sterategie: 
 changing a viral surface protein 
 using adapter proteins (which bridge the gap between the 
virus and the host cell) 
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NON-TRANSDUCTIONAL TARGETING 
involves altering the genome of the virus so it can 
only replicate in cancer cells, most frequently as part 
of the attenuation of the virus 
 
Include : 
 Transcriptional Targeting 
 Translational Targeting 
 Physiological Targeting 
 Micro-RNA  Targeting 
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TRANSCRIPTIONAL  TARGETING 
 For transcriptional targeting, which is only feasible 
for DNA viruses, the benefits of tissue (or tumor) 
specific promoters are exploited. 
 
 By placing an essential viral gene downstream of 
such cellular regulatory element in the viral 
genome, viral replication can be controlled.  
 
 Thus, progeny virus production will only be 
accomplished in cells expressing the selected 
promoter 
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TRANSLATIONAL  TARGETING 
 For RNA viruses, oncolytic virus specificity can 
be targeted by regulation of viral protein 
translation. 
 
 Inhibition of protein translation is a critical 
checkpoint to limit viral replication. 
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TRANSCRIPTIONAL  TARGETING  EXAMPLE 
 In one such approach, tumor-specific 
promoters were used to drive viral genes, as 
exemplified by adenovirus vectors, in which E1 
gene expression is driven by the human 
telomerase reverse transcriptase gene (hTERT) 
that is robustly expressed in cancer but not 
normal cells… 
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PHYSIOLOGICAL TARGETING 
 A third strategy to increase tumor specificity exploits cancer 
cell defects and mainly targets the often deficient antiviral 
responses of tumor cells…. 
 
 The most prominent example of physiological targeting 
exploits the interferon (IFN) signal transduction pathway…. 
 
 Infected healthy cells often produce IFN leading to an 
antiviral state of neighboring cells, while tumor cells often 
have defects in IFN signaling pathways resulting in the lack 
of a proper innate immune response against the virus…. 
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PHYSIOLOGICAL TARGETING 
 By genetic engineering of the viral genome 
such that immunomodulatory proteins are 
abolished, one can generate a virus that is 
vulnerable to antiviral responses in normal 
cells, but accomplishes replication and virus 
dissemination in tumor cells… 
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Interferon 
mechanism 
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MICRO-RNA  TARGETING 
 microRNAs manipulate the expression of genes by 
interacting with complementary target sequences 
in cellular messenger RNAs, reducing their 
translation or initiating their destruction. 
 
 the most recent oncolytic virus targeting strategy 
focuses on the differential expression of 
microRNAs (miRNAs) in normal and tumor cells. 
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MICRO-RNA  TARGETING 
 By incorporating miRNA target sequences 
corresponding to sequences of tissues specific 
cellular messenger RNAs into the viral genome, 
tumor-specific regulation of viral replication can 
be achieved… 
 
 This strategy is used to selectively eliminate the 
undesirable viral tropism by preventing its 
replication in normal tissues… 
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RUNAWAY FROM IMMUNITY  
 viruses are rapidly cleared from the circulation as a 
result of sequestration by the mononuclear phagocytic 
system (MPS) in the liver and spleen. 
 
 Before clearance, they are typically coated (opsonized) 
with antibodies, complement, coagulation factors 
and/or other serum proteins that facilitate their 
recognition by splenic macrophages and hepatic Kupffer 
cells.. 
 
 Also cellular immune response like interferon secreting 
can limite the virus… 
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RUNAWAY FROM IMMUNITY  
 Strategies to minimize sequestration include chemical modification of the coat 
proteins of the viruses by conjugation of biocompatible polymers, such as 
polyethylene glycol (PEG) and N-[2-hydroxypropyl] methaacrylamide (HPMA). 
 
 Both PEG and HPMA are already used clinically to prolong the circulation times of 
proteins and liposomes and to reduce off target toxicities. 
 
 An alternative approach to minimize sequestration of viruses (e.g. HSV) that are 
readily bound by IgM and complement proteins is to deplete these serum factors by 
pretreating with cobra venom factor or cyclophosphamide. 
 
 In contrast to normal cells, the successful tumor cell has often 
eliminated/inactivated key gene products that have the dual role of controlling 
critical cell growth/death programs and aiding in resisting virus infections. Because 
of these tumor-specific mutations, oncolytic Viruses can initiate productive infections 
in cancer cells. Occasionally, cancer cells are completely devoid of antiviral activity 
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FINAL GOAL : 
The ultimate challenge in the field of oncolytic virotherapy is to produce an “ideal”• oncolytic therapy that is: 
 
 Highly selective : able preferentially to seek and enter tumor cells while sparing non 
cancerous tissues and cells. 
 
 Replication competent:  maximally efficient in making copies of itself, amplifying in and 
destroying tumor cells 
 
 Well-tolerated:  having minimal side effects in cancer patients, and even more importantly,  non 
pathogenic; in human patients. 
 
 Carries little to no risk of genomic integration : viruses that do not integrate into the host cell 
DNA (replicate only in the cytoplasm) do not carry this risk, and therefore no risk of mutation. 
 
 Systemically administered : in metastatic disease, the most clinically relevant approach is to 
target and eliminate cancer cells, tumors and metastases wherever they are located in the 
body. 
 
 Able to carry therapeutic or diagnostic payloads directly to the tumor : specific strains 
of  oncolytic virus can be engineered to insert and express cancer-suppressing genes and/or 
anti-cancer therapies. 
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